
Paul Martens Janeski
Examiner (ID: 4040, Phone: (571)270-1681 , Office: P/3722 )
| Most Active Art Unit | 3722 |
| Art Unit(s) | 3726, 3722 |
| Total Applications | 635 |
| Issued Applications | 463 |
| Pending Applications | 0 |
| Abandoned Applications | 175 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18701342
[patent_doc_number] => 11787841
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Rationally-designed mutations to the thrA gene for enhanced lysine production in
[patent_app_type] => utility
[patent_app_number] => 17/319006
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 6633
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319006
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/319006 | Rationally-designed mutations to the thrA gene for enhanced lysine production in | May 11, 2021 | Issued |
Array
(
[id] => 17741495
[patent_doc_number] => 11389542
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-07-19
[patent_title] => Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
[patent_app_type] => utility
[patent_app_number] => 17/314563
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 20
[patent_no_of_words] => 101882
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314563
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314563 | Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation | May 6, 2021 | Issued |
Array
(
[id] => 17354595
[patent_doc_number] => 20220015391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => METHODS OF IMPROVING DESIRABLE TRAITS IN FOWL
[patent_app_type] => utility
[patent_app_number] => 17/306313
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66542
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306313
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306313 | METHODS OF IMPROVING DESIRABLE TRAITS IN FOWL | May 2, 2021 | Abandoned |
Array
(
[id] => 17124423
[patent_doc_number] => 20210299191
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/228146
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228146
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/228146 | COMPOSITIONS AND METHODS | Apr 11, 2021 | Abandoned |
Array
(
[id] => 18909310
[patent_doc_number] => 11872273
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Proteins and immunizing compositions containing
[patent_app_type] => utility
[patent_app_number] => 17/226761
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 39
[patent_no_of_words] => 32052
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226761
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/226761 | Proteins and immunizing compositions containing | Apr 8, 2021 | Issued |
Array
(
[id] => 18421588
[patent_doc_number] => 20230176052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => MYCOPLASMA PNEUMONIAE IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT
[patent_app_type] => utility
[patent_app_number] => 17/917622
[patent_app_country] => US
[patent_app_date] => 2021-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917622
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/917622 | MYCOPLASMA PNEUMONIAE IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT | Apr 5, 2021 | Pending |
Array
(
[id] => 18434359
[patent_doc_number] => 20230181653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => COMPOSITIONS FOR METABOLIC HEALTH
[patent_app_type] => utility
[patent_app_number] => 17/916242
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16952
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916242
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/916242 | COMPOSITIONS FOR METABOLIC HEALTH | Apr 4, 2021 | Abandoned |
Array
(
[id] => 19373937
[patent_doc_number] => 12065486
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
[patent_app_type] => utility
[patent_app_number] => 17/221177
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 18
[patent_no_of_words] => 15216
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221177
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221177 | VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor | Apr 1, 2021 | Issued |
Array
(
[id] => 18428710
[patent_doc_number] => 11673920
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Factor H binding protein variants and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/221646
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 40
[patent_no_of_words] => 28740
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221646
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221646 | Factor H binding protein variants and methods of use thereof | Apr 1, 2021 | Issued |
Array
(
[id] => 18273715
[patent_doc_number] => 11612636
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-28
[patent_title] => Method of treating autoimmune inflammatory crohn's disease
[patent_app_type] => utility
[patent_app_number] => 17/220573
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 26
[patent_no_of_words] => 16027
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220573
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/220573 | Method of treating autoimmune inflammatory crohn's disease | Mar 31, 2021 | Issued |
Array
(
[id] => 19324879
[patent_doc_number] => 12042532
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => Checkpoint inhibitor and a whole cell
[patent_app_type] => utility
[patent_app_number] => 17/301331
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 7871
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 228
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301331
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/301331 | Checkpoint inhibitor and a whole cell | Mar 30, 2021 | Issued |
Array
(
[id] => 16961628
[patent_doc_number] => 20210213127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/301319
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301319
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/301319 | CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY | Mar 30, 2021 | Abandoned |
Array
(
[id] => 18754047
[patent_doc_number] => 20230357418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => RESULTS OF EMPACTA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA
[patent_app_type] => utility
[patent_app_number] => 18/245372
[patent_app_country] => US
[patent_app_date] => 2021-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13501
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245372
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245372 | RESULTS OF EMPACTA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA | Mar 18, 2021 | Pending |
Array
(
[id] => 17113216
[patent_doc_number] => 20210293813
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => HIGH THROUGHPUT AFFINITY SAMPLE PREPARATION FOR MYCOTOXIN ANALYSIS
[patent_app_type] => utility
[patent_app_number] => 17/203920
[patent_app_country] => US
[patent_app_date] => 2021-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/203920 | High throughput affinity sample preparation for mycotoxin analysis | Mar 16, 2021 | Issued |
Array
(
[id] => 18737780
[patent_doc_number] => 20230346674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => Treatment of Upper Facial Lines
[patent_app_type] => utility
[patent_app_number] => 17/911503
[patent_app_country] => US
[patent_app_date] => 2021-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911503
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/911503 | Treatment of Upper Facial Lines | Mar 15, 2021 | Pending |
Array
(
[id] => 18347650
[patent_doc_number] => 20230135760
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => BIOCOMPOSITES COMPRISING PROBIOTICS, COLLAGEN AND BACTERIAL EXTRACELLULAR POLYSACCHARIDE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/911909
[patent_app_country] => US
[patent_app_date] => 2021-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911909
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/911909 | BIOCOMPOSITES COMPRISING PROBIOTICS, COLLAGEN AND BACTERIAL EXTRACELLULAR POLYSACCHARIDE AND USES THEREOF | Mar 14, 2021 | Pending |
Array
(
[id] => 17050722
[patent_doc_number] => 20210260156
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => PIRIN POLYPEPTIDE AND IMMUNE MODULATION
[patent_app_type] => utility
[patent_app_number] => 17/193348
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35658
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/193348 | PIRIN POLYPEPTIDE AND IMMUNE MODULATION | Mar 4, 2021 | Abandoned |
Array
(
[id] => 18295221
[patent_doc_number] => 20230104907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS PROTEIN ANTIGENS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/909423
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -88
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17909423
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/909423 | LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS PROTEIN ANTIGENS AND METHODS OF USE THEREOF | Mar 4, 2021 | Pending |
Array
(
[id] => 17053596
[patent_doc_number] => 20210263030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSIS
[patent_app_type] => utility
[patent_app_number] => 17/187264
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187264
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/187264 | IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSIS | Feb 25, 2021 | Abandoned |
Array
(
[id] => 17124418
[patent_doc_number] => 20210299186
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/180183
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15825
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180183 | VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER | Feb 18, 2021 | Abandoned |